• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

掀起屋顶:提高脊髓性肌萎缩症疗法的疗效。

Raise the Roof: Boosting the Efficacy of a Spinal Muscular Atrophy Therapy.

机构信息

Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA; Neurosciences Graduate Program, Stanford University School of Medicine, Stanford, CA 94305, USA.

Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA.

出版信息

Neuron. 2017 Jan 4;93(1):3-5. doi: 10.1016/j.neuron.2016.12.029.

DOI:10.1016/j.neuron.2016.12.029
PMID:28056344
Abstract

Spinal muscular atrophy is the most common genetic killer of infants. A therapy shows promise in the clinic, but there is a potential limit to its efficacy. In this issue of Neuron, d'Ydewalle et al. (2017) devise a new way to make it more effective.

摘要

脊髓性肌萎缩症是婴儿最常见的遗传杀手。一种疗法在临床上显示出前景,但它的疗效可能存在局限。在本期《神经元》杂志上,d'Ydewalle 等人(2017)设计了一种使它更有效的新方法。

相似文献

1
Raise the Roof: Boosting the Efficacy of a Spinal Muscular Atrophy Therapy.掀起屋顶:提高脊髓性肌萎缩症疗法的疗效。
Neuron. 2017 Jan 4;93(1):3-5. doi: 10.1016/j.neuron.2016.12.029.
2
The Antisense Transcript SMN-AS1 Regulates SMN Expression and Is a Novel Therapeutic Target for Spinal Muscular Atrophy.反义转录本SMN-AS1调节SMN表达,是脊髓性肌萎缩症的新型治疗靶点。
Neuron. 2017 Jan 4;93(1):66-79. doi: 10.1016/j.neuron.2016.11.033. Epub 2016 Dec 22.
3
Spinal muscular atrophy: diagnosis and management in a new therapeutic era.脊髓性肌萎缩症:新治疗时代的诊断与管理
Muscle Nerve. 2015 Feb;51(2):157-67. doi: 10.1002/mus.24497. Epub 2014 Dec 16.
4
Disease mechanisms and therapeutic approaches in spinal muscular atrophy.脊髓性肌萎缩症的疾病机制与治疗方法
J Neurosci. 2015 Jun 10;35(23):8691-700. doi: 10.1523/JNEUROSCI.0417-15.2015.
5
Therapeutics development for spinal muscular atrophy.脊髓性肌萎缩症的治疗研发
NeuroRx. 2006 Apr;3(2):235-45. doi: 10.1016/j.nurx.2006.01.010.
6
Advances and challenges in developing a therapy for spinal muscular atrophy.脊髓性肌萎缩症治疗方法开发的进展与挑战
Expert Rev Neurother. 2015;15(8):895-908. doi: 10.1586/14737175.2015.1059757.
7
Moving towards treatments for spinal muscular atrophy: hopes and limits.迈向脊髓性肌萎缩症的治疗:希望与局限
Expert Opin Emerg Drugs. 2015 Sep;20(3):353-6. doi: 10.1517/14728214.2015.1041375. Epub 2015 Jul 3.
8
Combination of SMN trans-splicing and a neurotrophic factor increases the life span and body mass in a severe model of spinal muscular atrophy.SMN 剪接异构体组合和神经营养因子增加严重脊髓性肌肉萎缩模型的寿命和体重。
Hum Gene Ther. 2011 Feb;22(2):135-44. doi: 10.1089/hum.2010.114. Epub 2010 Dec 19.
9
Mechanistic principles of antisense targets for the treatment of spinal muscular atrophy.用于治疗脊髓性肌萎缩症的反义靶点的作用机制原理
Future Med Chem. 2015;7(13):1793-808. doi: 10.4155/fmc.15.101. Epub 2015 Sep 18.
10
Established Stem Cell Model of Spinal Muscular Atrophy Is Applicable in the Evaluation of the Efficacy of Thyrotropin-Releasing Hormone Analog.已建立的脊髓性肌萎缩症干细胞模型可用于评估促甲状腺激素释放激素类似物的疗效。
Stem Cells Transl Med. 2016 Feb;5(2):152-63. doi: 10.5966/sctm.2015-0059. Epub 2015 Dec 18.

引用本文的文献

1
Pioneering SMA therapies for all types: survival gains, cost dynamics, and performance-based agreements.针对所有类型脊髓性肌萎缩症的开创性疗法:生存获益、成本动态及基于疗效的协议
Cost Eff Resour Alloc. 2025 Aug 5;23(1):40. doi: 10.1186/s12962-025-00647-3.
2
The development and controversy of competitive endogenous RNA hypothesis in non-coding genes.非编码基因中竞争内源性 RNA 假说的发展与争议。
Mol Cell Biochem. 2021 Jan;476(1):109-123. doi: 10.1007/s11010-020-03889-2. Epub 2020 Sep 25.
3
Spinal Muscular Atrophy Modeling and Treatment Advances by Induced Pluripotent Stem Cells Studies.
诱导多能干细胞研究在脊髓性肌萎缩症建模和治疗方面的进展。
Stem Cell Rev Rep. 2019 Dec;15(6):795-813. doi: 10.1007/s12015-019-09910-6.
4
Small-molecule flunarizine increases SMN protein in nuclear Cajal bodies and motor function in a mouse model of spinal muscular atrophy.小分子氟桂利嗪增加核 Cajal 体中的 SMN 蛋白,并改善脊髓性肌萎缩症小鼠模型的运动功能。
Sci Rep. 2018 Feb 1;8(1):2075. doi: 10.1038/s41598-018-20219-1.